Ozempic vs Mounjaro vs Wegovy vs Zepbound: The Full Comparison

Four GLP-1 medications dominate the weight loss conversation in 2026: Ozempic, Mounjaro, Wegovy, and Zepbound. While they share the same mechanism of action at a high level, there are important differences in effectiveness, FDA approvals, pricing, and side effects. This guide provides the definitive head-to-head comparison to help you and your doctor choose the right medication.

The Quick Overview

Semaglutide vs Tirzepatide: The Core Difference

The most important distinction is between the two active ingredients. Semaglutide (in Ozempic and Wegovy) is a GLP-1 receptor agonist that mimics one gut hormone. Tirzepatide (in Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist that mimics two gut hormones. This dual action is why tirzepatide generally produces greater weight loss in clinical trials.

In the SURMOUNT-1 trial, tirzepatide at the highest dose (15mg) led to an average weight loss of 22.5% of body weight over 72 weeks. In the STEP 1 trial, semaglutide at 2.4mg led to approximately 15% weight loss over 68 weeks. While these are averages and individual results vary considerably, the edge for tirzepatide is consistent across studies.

Ozempic vs Wegovy: Same Drug, Different Approvals

Ozempic and Wegovy contain the same active ingredient (semaglutide) but at different maximum doses and with different FDA approvals. Ozempic is approved only for type 2 diabetes with a maximum dose of 2.0mg per week. Wegovy is approved specifically for chronic weight management at 2.4mg per week.

Some providers prescribe Ozempic off-label for weight loss because it is sometimes easier to obtain through insurance for diabetes coverage. However, this practice has drawbacks. You may not be able to reach the optimal weight loss dose, and insurance coverage can be denied if the prescription does not match the approved indication.

Mounjaro vs Zepbound: Same Story, Different Label

Similarly, Mounjaro and Zepbound both contain tirzepatide. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for weight management. The dosing is identical for both, going up to 15mg per week. Zepbound's FDA label for obesity makes it the preferred choice for insurance coverage when prescribed for weight loss without a diabetes diagnosis.

Side Effect Comparison

Both medication classes share similar gastrointestinal side effects. In head-to-head comparisons, the profile is remarkably similar:

• Nausea: Affects 40-44% of semaglutide users and 29-35% of tirzepatide users
• Diarrhea: Affects 30% of semaglutide users and 23-25% of tirzepatide users
• Constipation: Affects 24% of semaglutide users and 20-23% of tirzepatide users
• Vomiting: Affects 24% of semaglutide users and 12-18% of tirzepatide users

Interestingly, tirzepatide tends to produce somewhat fewer gastrointestinal side effects despite producing greater weight loss. This may be related to the GIP component of the dual-agonist mechanism, though the exact reason is still under investigation.

Insurance and Cost Considerations

Cost often determines which medication patients end up taking. Insurance formularies vary widely. Some plans cover Wegovy but not Zepbound, or vice versa. Some cover neither for weight loss but will cover Ozempic or Mounjaro for diabetes. Both manufacturers offer savings programs that can significantly reduce out-of-pocket costs for commercially insured patients.

If cost is your primary concern, read our detailed guide on finding the cheapest safe GLP-1 program, which covers all available cost-reduction strategies including manufacturer coupons, insurance appeals, and alternative sourcing.

Cardiovascular Benefits

Semaglutide has a significant advantage in cardiovascular data. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) for semaglutide users. This led to Wegovy receiving an additional FDA indication for cardiovascular risk reduction in obese patients.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) has shown promising results, with data suggesting potential cardiovascular benefits, but it has not yet received a specific cardiovascular indication from the FDA. For patients with significant cardiovascular risk factors, this distinction may favor semaglutide.

Which One Should You Choose?

There is no universally right answer. Here is a framework for decision-making:

• Choose Wegovy/semaglutide if: you have cardiovascular risk factors, your insurance covers it, or you prefer the medication with longer real-world safety data
• Choose Zepbound/tirzepatide if: maximum weight loss is your priority, you have had significant GI side effects with semaglutide, or your insurance prefers Eli Lilly products
• Consider Ozempic/Mounjaro if: you also have type 2 diabetes, as these are the diabetes-approved versions that may be easier to cover through insurance

The most important factor is working with a qualified provider who can evaluate your specific health situation and guide you toward the right choice. Before choosing a provider, especially an online one, verify their legitimacy by checking their licensing and patient reviews.

The Bottom Line

All four medications are effective tools for weight management. Tirzepatide (Zepbound/Mounjaro) edges out semaglutide (Wegovy/Ozempic) on raw weight loss numbers and may cause fewer GI side effects. Semaglutide has stronger cardiovascular data and a longer track record. The best medication for you depends on your health profile, insurance coverage, and personal goals. Have an informed conversation with your healthcare provider using this guide as a starting point.